Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software
Siemens Healthineers AG (ETR: SHL) has entered into a strategic collaboration with Ruijin Hospital, a...
Deals
Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...
Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model
Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122) announced the renewal of its long-standing supply,...
Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform
Xellar Biosystems, a U.S.-based pioneer in “AI + organ-on-a-chip” technology, announced the successful completion of...
Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an exclusive strategic partnership with TriNetX, Inc., granting Regeneron...
Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced a strategic partnership with Sihuan...
Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal
Guizhou Sanli Pharmaceutical Co., Ltd. (SHA: 603439) announced the transfer of marketing authorizations and comprehensive...
Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer
Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Amgen Inc. (NASDAQ: AMGN) announced a strategic collaboration...
Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms
Shanghai BDgene Technology Co., Ltd. announced the successful closing of a financing round securing hundreds...
Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing...
Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to...
Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech...
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc....
Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
Abbott (NYSE: ABT) has announced a strategic collaboration with Flatiron Health, a leading oncology health...
Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I...
Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Kailera Therapeutics has announced plans for an initial public offering (IPO) to secure additional funding...
Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with...
AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an...
Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi’an-based developer of bifunctional and multi-functional peptide therapeutics,...
Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo...